Richard Wasserman, MD
Allergy & Immunology · Dallas, TXNPI 1346234614
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (58.8%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 30 manufacturers reported payments, led by Grifols USA, LLC at 39.2% of the total. Reporting peaked in 2023 at $119,905 and has fallen 86.9% since, to $15,660 in 2025. Among allergy & immunology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 471 payments — averaging $959.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Grifols USA, LLC$177K
- GSK$121K
- Takeda Pharmaceuticals U.S.A., Inc.$44K
- Shire North American Group Inc$32K
- CSL Behring$32K
- ADMA Biomanufacturing LLC$13K
- plus $34K from 24 others
Across 312 payments — averaging $4794.62 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$575K
- Grifols Therapeutics LLC$237K
- Kedrion S.p.a.$180K
- Shire North American Group Inc$172K
- AstraZeneca$140K
- CSL Behring$106K
- plus $86K from 3 others
Across 2 payments — averaging $996.25 each. An ownership or investment interest held by the physician or an immediate family member.
- Consortium Of Independent Immunology Clinics, LLC$2K
What the payments were for
- Consulting fees$149,30033%
- Speaking & faculty fees$265,93359%
- Travel & lodging$28,5336%
- Food & beverage$8,1052%
- Education$1750%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Grifols USA, LLC | 133 | $177,087 |
| GSK | 103 | $120,566 |
| Takeda Pharmaceuticals U.S.A., Inc. | 34 | $44,113 |
| Shire North American Group Inc | 34 | $31,737 |
| CSL Behring | 46 | $31,618 |
| ADMA Biomanufacturing LLC | 9 | $13,225 |
| Aimmune Therapeutics, Inc. | 7 | $7,580 |
| Sanofi | 9 | $7,429 |
| Pfizer | 27 | $6,729 |
| Grifols Shared Services North America, Inc. | 3 | $2,761 |
| Pharming Healthcare, Inc. | 9 | $2,753 |
| GC Biopharma USA, Inc. | 2 | $2,025 |
| AstraZeneca | 17 | $1,530 |
| Alk-abello, Inc | 3 | $960 |
| Consortium Of Independent Immunology Clinics, LLC | 1 | $750 |
| Regeneron Healthcare Solutions, Inc. | 3 | $251 |
| Octapharma USA, Inc. | 7 | $161 |
| Biocryst US Sales Co., LLC | 2 | $139 |
| Genentech, Inc. | 1 | $132 |
| Blueprint Medicines Corporation | 1 | $125 |
| Hospira, Inc. | 5 | $80 |
| Novartis | 3 | $78 |
| Teva Pharmaceuticals USA, Inc. | 3 | $52 |
| Kaleo, Inc. | 2 | $45 |
| Amgen | 2 | $31 |
| Sanofi-aventis U.S. LLC | 1 | $29 |
| Kedrion Biopharma, Inc. | 1 | $24 |
| Tersera Therapeutics LLC | 1 | $17 |
| Phadia US Inc. | 1 | $15 |
| Genentech USA, Inc. | 1 | $5 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$452,045 in reported general payments places this provider in the 95th percentile of 336 allergy & immunology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 29 | $228,926 |
| CuvitruImmun Glob G(Igg)/Gly/Iga Ov50 | 41 | $135,479 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 11 | $110,115 |
| Advair HfaFluticasone Propion/Salmeterol | 20 | $6,933 |
| Itraconazole | 11 | $2,133 |
| Levalbuterol Tartrate HfaLevalbuterol Tartrate | 11 | $604 |
| Fluticasone Propionate | 15 | $285 |
| Azelastine Hcl | 17 | $235 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 12 | $202 |
| Omeprazole | 12 | $147 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Cuvitru, Gammagard Liquid | $44,113 | $245,59452 claims |
| CSL BehringPrivigen | $31,618 | $228,92629 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 336 allergy & immunology providers in Texas.
Other allergy & immunology in Dallas
- Matthew FeldmanDallas$410K
- Lara GrossDallas$171K
- Sonak DaulatDallas$72K
- Joseph WestDallas$39K
- Anil NandaDallas$35K
- Joseph DiazSan Antonio$1.1M
- Lukena KarkhanisSan Antonio$377K
- Paul VigoAustin$304K
- Neha ReshamwalaAustin$303K
- Bobby LanierBenbrook$149K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.